The whole point of the lumps pathway is to separate the rare soft-tissue sarcoma from the very common benign lump, because the cost of missing it — or worse, excising it unplanned — is high. NICE NG12 gives a memorable rule: size over 5 cm, depth to fascia, increasing size, pain, or recurrence after excision each warrant urgent ultrasound and referral. The cardinal error is treating such a lump as a lipoma and shelling it out, which contaminates tissue planes and compromises definitive surgery and prognosis. Bone masses and suspicious lymph nodes have their own NG12 routes.

History triages the lump along a single axis: how it is behaving over time. A soft, mobile lump that has been unchanged for years is almost always benign, whereas any lump that is new, growing, or has recurred after a previous "lipoma" excision earns imaging. Pain is a useful but asymmetric clue — its presence is a red flag, but its absence is not reassuring because many sarcomas are painless. Systemic B-symptoms point towards lymphoma, and a relevant syndrome (such as neurofibromatosis) changes the pre-test probability of malignant transformation.

A structured examination of the lump — site, size, shape, surface and consistency, plus depth — captures the features that drive the decision. Benign lumps tend to be superficial, soft or fluctuant, mobile and well-defined (a lipoma slips under the finger; a cyst transilluminates and may have a punctum). The features that move a lump onto the sarcoma pathway are size over 5 cm, a deep (sub-fascial) position, fixation, and hard irregular consistency. Documenting size in centimetres also creates the baseline against which growth — the most important sign — is later judged.

The differential is dominated by a few benign diagnoses — lipoma, epidermoid cyst, ganglion and reactive lymph node — each with a recognisable bedside signature. Holding the malignant possibilities alongside them (sarcoma, lymphoma, metastasis) is what keeps the pathway safe, because a deep, growing "lipoma" is exactly how a sarcoma presents. Trauma-related lumps (haematoma, fat necrosis) and infective ones (abscess) are common confounders that should declare themselves on history and examination but can also mimic, so persistence or atypical behaviour still prompts imaging.

Imaging, not surgery, is the first investigation for any lump that is not clearly a simple benign lesion. Ultrasound is the accessible first-line test that distinguishes cystic from solid, gauges size and depth, and flags the lesions that need the sarcoma service, where MRI and image-guided biopsy are performed in a planned way. The non-negotiable rule is that biopsy and excision of a possible sarcoma belong to the MDT: an unplanned local procedure contaminates the tissue planes that the definitive operation must clear, and demonstrably worsens outcomes.

Referral follows the red-flag assessment directly. The headline route is the NG12 soft-tissue sarcoma pathway — triggered by size, depth, growth, pain or recurrence, usually after an urgent ultrasound — with parallel routes for bone sarcoma (urgent X-ray then 48-hour referral) and for suspicious lymphadenopathy (lymphoma 2WW). Everything that is confidently benign and merely symptomatic goes via routine surgical or dermatology routes for removal, while infective and vascular masses have their own urgent destinations. The skill is matching the lump to the correct pathway rather than defaulting to local excision.

For the genuinely benign lumps, management is mostly reassurance with selective removal for symptoms, cosmesis or diagnostic doubt — a confirmed small lipoma or a quiescent cyst needs nothing more than safety-netting. Two rules keep this safe. First, every excised lump is sent for histology, which is the final net that catches an unexpected sarcoma. Second, no lump with sarcoma features is ever excised locally; it is imaged and referred. Abscesses are drained, with antibiotics reserved for surrounding cellulitis or systemic involvement.

Because the great majority of lumps are benign, the most valuable intervention is clear, specific reassurance paired with equally specific safety-netting. Patients remember concrete triggers — rapid growth, new pain, size beyond about 5 cm, fixation or skin change — far better than a vague instruction to return if worried. After any excision, closing the loop on histology is part of safe care, and patients with predisposing syndromes such as neurofibromatosis need to know which changes in a known lump should prompt urgent review.

Safety-netting is what makes a "benign lump" diagnosis safe over time, because the single most important sarcoma sign — growth — only declares itself later. Documenting size in centimetres creates the baseline, and the patient leaves knowing the specific changes that mandate re-imaging and referral. Two systems-level nets matter just as much: ensuring every excised lump’s histology is reviewed and acted on, and treating any recurrence at a previous excision site as a sarcoma red flag regardless of what the first specimen was labelled.